Monday, November 6, 2017

High Importance!! Owner of Florida Pharmacy Pleads Guilty in $100 Million Compounding Pharmacy Fraud Scheme; Real Properties, Cars and a 50-Foot Boat Will Be Forfeited Seven Others Previously Pleaded Guilty

Department of Justice
Office of Public Affairs

FOR IMMEDIATE RELEASE
Monday, November 6, 2017

Owner of Florida Pharmacy Pleads Guilty in $100 Million Compounding Pharmacy Fraud Scheme; Real Properties, Cars and a 50-Foot Boat Will Be Forfeited

Seven Others Previously Pleaded Guilty

The president and owner of a Florida pharmacy that was at the center of a massive compounding pharmacy fraud scheme, which impacted private insurance companies, Medicare and TRICARE, pleaded guilty today for his role in the scheme.  Seven other individuals have previously pleaded guilty in connection to the scheme.  Various real properties, cars and a 50-foot boat will be forfeited as part of the guilty pleas. 

Acting Assistant Attorney General Kenneth A. Blanco of the Justice Department’s Criminal Division, Acting U.S. Attorney W. Stephen Muldrow of the Middle District of Florida, Special Agent in Charge Eric W. Sporre of the FBI’s Tampa Field Office, Special Agent in Charge Robert F. Lasky of the FBI’s Miami Field Office, Special Agent in Charge Shimon Richmond of the U.S. Department of Health and Human Services Office of Inspector General’s (HHS-OIG) Miami Regional Office and Resident Agent in Charge Brooke Harris of the U.S. Defense Criminal Investigative Service’s (DCIS) Tampa Regional Office made the announcement.

Nicholas A. Borgesano Jr., 45, of New Port Richey, Florida, the president and owner of A to Z Pharmacy of New Port Richey, pleaded guilty in the Middle District of Florida to one count of conspiracy to commit health care fraud and one count of conspiracy to engage in monetary transactions involving criminally derived property.  His sentencing will be scheduled before U.S. District Judge James S. Moody Jr of the Middle District of Florida.  

According to admissions made as part of his plea agreement, Borgesano owned and operated numerous pharmacies and shell companies that he and his co-conspirators used to execute a fraud scheme involving prescription compounded medications.  The scheme generated over $100 million in fraud proceeds, he admitted.  Borgesano acquired and controlled A to Z Pharmacy in New Port Richey, Havana Pharmacy, Medplus/New Life Pharmacy and Metropolitan Pharmacy, all of Miami; and Jaimy Pharmacy and Prestige Pharmacy, both of Hialeah, Florida.  He admitted using these pharmacies to cause the submission of false and fraudulent reimbursement claims for prescription compounded medications, chiefly pain creams and scar creams, to private insurance companies, Medicare and TRICARE.  Borgesano admitted that he and his co-conspirators manipulated billing codes in the reimbursement claims and submitted reimbursement claims for pharmaceutical ingredients they did not have.  Borgesano and his co-conspirators also paid kickbacks and bribes in exchange for prescriptions and patient identifying information used to further the scheme, including to a physician in exchange for the physician signing prescriptions for patients he never saw.  Borgesano admitted using A to Z Pharmacy as the hub of his operation on behalf of all his pharmacies.  He disbursed proceeds of the fraud scheme through a variety of methods, including by check and wire transfer to co-conspirators’ shell companies and through the purchase of assets, he admitted. 

In addition to Borgesano, the following defendants have previously pleaded guilty to conspiracy to commit health care fraud for their roles in the scheme:

  • Bradley Sirkin, 55, of Boca Raton, Florida;
  • Scott P. Piccininni, 49, of Fort Lauderdale, Florida;
  • Edwin Patrick Young, 49, of New Port Richey, Florida;
  • Wayne M. Kreisberg, 40, of Parkland, Florida;
  • Matthew N. Sterner, 48, of New Port Richey, Florida;
  • Peter B. Williams, 57, of New Port Richey, Florida; and
  • Joseph Degregorio, 71, of New Port Richey, Florida

The cars that will be forfeited include a 1936 Ford Deluxe, a 1964 Chevrolet Corvette convertible, a 1967 Chevrolet Camaro, a 1970 Chevrolet Monte Carlo and a 2008 Lamborghini convertible.  The boat that will be forfeited is a 2009 50’7” Cigarette racing boat.   The cars and boat had previously been seized.  The combined equity in the real properties, cars and boat that will be forfeited is over $7.6 million.  The real properties, cars and boat had been purchased with proceeds from the fraud scheme. 

This case was investigated by the FBI with support from HHS-OIG and DCIS and was brought as part of the Medicare Fraud Strike Force, under the supervision of the Criminal Division’s Fraud Section and the U.S. Attorney’s Office for the Middle District of Florida.  The case is being prosecuted by Senior Trial Attorney Christopher J. Hunter and Trial Attorney Timothy P. Loper of the Fraud Section.

The Fraud Section leads the Medicare Fraud Strike Force, which is part of a joint initiative between the Department of Justice and HHS to focus their efforts to prevent and deter fraud and enforce current anti-fraud laws around the country.  The Medicare Fraud Strike Force operates in nine locations nationwide.  Since its inception in March 2007, the Medicare Fraud Strike Force has charged over 3,500 defendants who collectively have falsely billed the Medicare program for over $12.5 billion.
Press Release Number: 
17-1246

How Doctors Are Getting Rich on Urine Tests for Opioid Patients Want to turn that pain clinic into a real moneymaker? Open your own urine-testing lab and start billing Medicare. Fred Schulte and Elizabeth Lucas from Kaiser Health News November 6, 2017, 4:00 AM CST

‘Unprecedented’ Pentagon health committee could undermine FDA POLITICO

‘Unprecedented’ Pentagon health committee could undermine FDA
POLITICO
FDA currently has sole authority to authorize drugs and devices for emergency use. Read the full story

Statement from FDA Commissioner Scott Gottlieb, M.D., on implementation of agency’s streamlined development and review pathway for consumer tests that evaluate genetic health risks

Statement from FDA Commissioner Scott Gottlieb, MD, on ...

FDA.gov-1 hour ago
Statement from FDA Commissioner Scott Gottlieb, M.D., on implementation of agency's streamlined development and review pathway for consumer tests that ...

CVS to offer nationwide next-day delivery in preemptive shot at ...

USA TODAY-2 hours ago
The company's pharmacy services division, which manages drug benefits as an intermediary between insurers and drug companies, grew into an even bigger ...

PDL practice alert: compliance with compounding guidelines

PDL practice alert: compliance with compounding guidelines

Australian Journal of Pharmacy (blog)-8 hours ago
Compounding pharmacists are reminded to be familiar with the Pharmacy Board of Australia's (PBA) Guidelines on the Compounding of Medicines published in ...

Saturday, November 4, 2017

11/03/2017Fresenius Kabi USA  Midazolam Injection, USP prefilled syringe  MislabeledFresenius Kabi USA

Friday, November 3, 2017

6 ways the proposed Republican tax overhaul could impact pharma

Becker's Hospital Review-6 hours ago
The legislation would eliminate tax credit for orphan drugs. The bill includes a provision that would repeal a tax break that pharmaceutical companies can get for 

House Republicans Aim To Eliminate Tax Credits For Orphan Drugs

NPR-10 hours ago
For more than three decades, pharmaceutical companies have claimed a 50 percent tax ... Companies whose drugs are deemed orphans by the Food and Drug ...

Attorneys general seek to broaden lawsuit alleging pharmaceutical ...

Hopkinsville Kentucky New Era-10 hours ago
... pending multistate lawsuit that alleges widespread collusion among pharmaceutical companies to reduce competition and increase the price of generic drugs.

EpiPen Failures Cited in Seven Deaths This Year, FDA Files Show

Washington Post-7 hours ago
The FDA received 228 reports of EpiPen or EpiPen Jr. failures during that period, according to documents made available as a result of a Freedom of Information ...
Health Highlights: Nov. 3, 2017
Philly.com-13 hours ago

Why Isn't It Mandatory For Doctors To Use A State Drug Monitoring ...

WFSU-5 hours ago
Jackson's shop is a compounding pharmacy, and he ex

Horseracing Integrity Act Of 2017 Draws Support Of 100 House Representatives by Press Release | 11.01.2017 | 6:41pm

China Disputes Trump's Claims of Fentanyl 'Flood' Into United States Nov. 3, 2017, at 2:21 a.m.

Distraught women tell court how illegal fake Botox left them disfigured, looking 'like a hamster'

Racing Commissioners International

https://arci-members.azurewebsites.net/publicpages/publicrulings.asp
9 hours ago - Jurisdiction: Oklahoma Horse Racing Commission, Facility: Remington Park. Ruling Number: 17-RP-120, Ruling Type: Medication/Drug/Alcohol Violation -

Man Pleads Guilty To Selling Misbranded Horse Drugs

Man Pleads Guilty To Selling Misbranded Horse Drugs

Maine Public-3 hours ago
Court documents say he operated a business in New York that sold dietarysupplements, intravenous drugs and other supplies for horses. Prosecutors say .

US District Court Sanctions Weight-Loss Supplement Marketers for claims

US District Court Sanctions Weight-Loss Supplement Marketers for ...

Lexology-2 hours ago
The FTC alleged that, in 2009, the defendants were violating the 2008 order by marketing four new dietary supplements with weight-loss claims that lacked the ...

Can You Trust the Labels on Your Supplements?

Can You Trust the Labels on Your Supplements?

WebMD-21 hours ago
More than half of the herbal and dietary supplements analyzed by researchers ... Bodybuilding and weight-loss supplements, in particular, tended to contain .
Department of Justice
U.S. Attorney’s Office
Western District of Pennsylvania

FOR IMMEDIATE RELEASE
Thursday, November 2, 2017

Dentist Charged with Unlawful Distribution of Controlled Substances, Health Care Fraud, and Omitting Information on DEA Form

PITTSBURGH - A resident of Pittsburgh, Pennsylvania, has been indicted by a federal grand jury in Pittsburgh, Pennsylvania, on charges of Distribution of Hydrocodone and Oxycodone, Schedule II and III controlled substances, outside the usual course of professional practice; Using or Maintaining a Drug-Involved Premises; Health Care Fraud; and Omitting Material Information From Required Reports, Records, and Other Documents, Acting United States Attorney Soo C. Song announced today.
The 200-count superseding indictment named Daniel Garner, 45, a dentist who practiced in Pittsburgh, Pennsylvania, as the sole defendant.
According to the Superseding Indictment, from on or about November 13, 2012, through on or about June 11, 2015, Garner distributed Hydrocodone and/or Oxycodone, Schedule II and III controlled substances, on 196 occasions, outside the usual course of professional practice. The Superseding Indictment also alleges that from in and around July 2011 through in and around March 2015 and from in and around March 2015 through in and around August 2015, Garner knowingly and intentionally used and maintained his dental office for the purpose of unlawfully distributing controlled substances. Further, the Superseding Indictment alleges that from in and around February 2010 through in and around August 2015, Garner committed health care fraud. The Superseding Indictment further alleges that on January 14, 2016, Garner omitted material information from an application for a Drug Enforcement Agency registration number.
The law provides for a maximum total sentence on all counts of incarceration of up to 3,974 years, a fine of $197,500,000, a term of supervised release of 598 years, or all. Under the Federal Sentencing Guidelines, the actual sentence imposed would be based upon the seriousness of the offenses and the prior criminal history, if any, of the defendant.
Assistant United States Attorney Cindy K. Chung is prosecuting this case on behalf of the government.
The Drug Enforcement Administration and the Federal Bureau of Investigation conducted the investigation that led to the prosecution of Daniel Garner.
Topic(s): 
Healthcare Fraud
Department of Justice
U.S. Attorney’s Office
Eastern District of Texas

FOR IMMEDIATE RELEASE
Thursday, November 2, 2017

Final Defendants Sentenced in Synthetic Drug Distribution Conspiracy

TYLER, Texas – A mother and son have been sentenced to federal prison for their roles in a synthetic drug conspiracy in the Eastern District of Texas, announced Acting U.S. Attorney Brit Featherston today.

Sharjeel Jeff Ali, 29, and his mother, Nadia Farishta, 54, both of Dallas, pleaded guilty in June 2017 to conspiracy to distribute and possession with intent to distribute Schedule I controlled substances, conspiracy to distribute and possession with intent to distribute controlled substance analogues, and engaging in monetary transactions.  Ali was sentenced to 30 months in federal prison today by U.S. District Judge Thad Heartfield.  Farishta was sentenced to 47 months in federal prison today.

Earlier this year, Farishta's ex-husband, Saleem Jiwani, of Tyler, was sentenced to 60 months in federal prison; her daughter, Nimrose Khan, of Carrollton, was sentenced to 24 months in federal prison; and her son-in-law, Adeel Khan, of Carrollton, was sentenced to 30 months in federal prison; for similar charges.

The defendants will forfeit over $250,000 in seized United States currency and bank accounts, approximately 55 pounds of synthetic drugs, and drug paraphernalia. The United States will also take money judgments in the amount of $500,000 against Jiwani and Farishta.

The family members were indicted by a federal grand jury on Aug. 3, 2016. According to the indictment, synthetic drugs were distributed by the co-conspirators from the Ashes Smoke Shop located in downtown Plano, Texas, and by Jiwani at the Minute Stop convenience store located in Tyler, Texas. Charges included conspiracy to distribute and possess with intent to distribute Schedule I controlled substances; conspiracy to distribute and possess with intent to distribute controlled substance analogues; conspiracy to commit offenses against the United States; conspiracy to sell and offer for sale drug paraphernalia; engaging in monetary transactions in property derived from specified unlawful activity and aiding and abetting; and maintaining a place for the distribution of a controlled substance or controlled substance analogue and aiding and abetting. 

“The scourge of illegal drug use in our community is as great now as ever before” said Acting U.S. Attorney Featherston.  “In this case, the selling of chemically laced leaves and other substances to be sold as fake marijuana to young people is reckless. No one has any idea what exactly was sprayed onto the “K-2” substance, yet these synthetic drugs were sold for lots of money.  It’s crazy to me that people will ingest these so called “synthetic” drugs with nothing more than a guess as to what high or harm it will do to them. The investigators and prosecutors did a great job in putting this case together.”


On Aug. 4, 2016, a combined task force of federal, state and local law enforcement executed federal arrest and search warrants in Plano, Carrollton, Dallas, and Tyler, Texas as a result of a joint investigation by the U.S. Drug Enforcement Administration; Plano Police Department; Internal Revenue Service-Criminal Investigation; Bureau of Alcohol, Tobacco, Firearms and Explosives Asset Forfeiture and Seized Property Division; and Smith County Sheriff’s Office. This case was prosecuted by Assistant U.S. Attorney Mary Ann Cozby.

Topic(s): 
Drug Trafficking
Component(s): 

Thursday, November 2, 2017

Tyler, Texas Smith County Man Sentenced for Importing Anabolic Steroids

Department of Justice
U.S. Attorney’s Office
Eastern District of Texas

FOR IMMEDIATE RELEASE
Thursday, November 2, 2017

Smith County Man Sentenced for Importing Anabolic Steroids

            TYLER, Texas – A 45-year-old Tyler man has been sentenced to federal prison for drug trafficking violations in the Eastern District of Texas, announced Acting U.S. Attorney Brit Featherston today.

Stacey Godsey pleaded guilty on July 5, 2017 to conspiracy to import anabolic steroids and was sentenced to 24 months in federal prison today by U.S. District Judge Thad Heartfield. 

According to information presented in court, from 2014 to 2016, Godsey and Joseph Shay Burton, 39, also of Tyler, purchased anabolic steroids through the internet from suppliers located in China.  The steroids were shipped to the United States where Godsey and Burton converted them from powder to liquid dosage units in the kitchen and garage of Godsey's residence.  Once converted into liquid dosage units, the steroids were sold and distributed to steroid users in Tyler, Texas and elsewhere.  In the spring of 2016, law enforcement officers searched residences belonging to Godsey and Burton.  More than 60,000 dosage units of anabolic steroids were found at Godsey's residence.  More than 6,000 dosage units were found at Burton's residence.

            Burton also pleaded guilty in July 2017 and is awaiting sentencing.

This casewas investigated by the Drug Enforcement Administration, the Tyler Police Department, and the Smith County Sheriff's Office and prosecuted by Assistant U.S. Attorney Nathaniel C. Kummerfeld.

Topic(s): 
Drug Trafficking
Component(s): 

Former Chief Financial Officer Of Osiris Therapeutics, Inc.(,a developer and producer of regenerative medicine products), Pleads Guilty To Lying To Auditors

Department of Justice
U.S. Attorney’s Office
Southern District of New York

FOR IMMEDIATE RELEASE
Thursday, November 2, 2017

Former Chief Financial Officer Of Osiris Therapeutics, Inc., Pleads Guilty To Lying To Auditors

Joon H. Kim, the Acting United States Attorney for the Southern District of New York, and Philip R. Bartlett, Inspector-in-Charge of the New York Office of the U.S. Postal Inspection Service (“USPIS”), announced that PHILIP JACOBY, the former chief financial officer of Osiris Therapeutics, Inc. (“Osiris”), a developer and producer of regenerative medicine products, was charged by criminal information (the “Information”) and pled guilty today to lying to Osiris’s auditors in connection with the auditors’ review of Osiris’s 2014 10-K and Third Quarter 2015 10-Q filings.  JACOBY pled guilty before U.S. District Judge Denise Cote.

Acting Manhattan U.S. Attorney Joon H. Kim said:  “Philip Jacoby, the former CFO of a pharmaceutical company, admitted today to lying to auditors conducting an examination of the financial well-being of his company.  Jacoby fabricated documents, made false statements, and asked others to backdate critical transactions in furtherance of his scheme to mislead auditors. For his criminal conduct, which ultimately misled those looking to invest in his publicly traded company, Jacoby faces time in federal prison.”

Inspector-in-Charge Philip R. Bartlett said:  “In a misguided effort to avoid a restatement of Osiris’s fourth quarter revenue numbers, Philip Jacoby lied about the conversion of $1.1 million dollars of consignment inventory to a final sale.  He wasn’t so clever when he left a paper trail of evidence Postal Inspectors followed right back to him.”

According to allegations contained in the Information and statements made in public Court proceedings:

Osiris, headquartered in Columbia, Maryland, is a publicly traded company specializing in the research, development, and marketing of regenerative medicine products.  Osiris sold its products either through its direct sales force, or, more typically, through numerous distributors.  Osiris’s securities traded under the symbol “OSIR” on the NASDAQ stock exchange. 

From in or about 2008 up to and including in or about September 2015, JACOBY held the position of chief financial officer (“CFO”) of Osiris.  From in or about September 2015 through in or about January 2016, JACOBY held the position of principal accounting officer.  During the period that JACOBY was the CFO of Osiris, he signed Osiris’s quarterly and yearly financial reports.  These reports were required to be filed with the United States Securities and Exchange Commission (“SEC”) and provided the investing public with information regarding Osiris’s financial performance.

Although Osiris was initially a research and development company, by at least in or about 2014, Osiris’s management was focused on the company’s “top line,” or gross revenue growth.  Osiris was especially focused on being able to demonstrate quarter-over-quarter revenue growth, that is, reporting revenue for each quarter that was greater than the previous quarter’s.  For example, a former CEO of Osiris (the “CEO”) regularly prepared internal presentations emphasizing the company’s historical quarter-over-quarter revenue growth and emphasizing the need to achieve future growth.  Similarly, in public earnings calls run by the CEO and in its earnings press releases, Osiris touted its revenue performance and quarter-over-quarter revenue growth. 
Improper Accounting at Osiris With Respect to Distributor-1
Between approximately 2010 and approximately 2015, Distributor-1 was a distributor for Osiris’s Ovation product, among other products.  Distributor-1 was owned in its entirety by a sole principal (“Owner-1”).
In or about September 2013, the Food and Drug Administration (“FDA”) informed Osiris that Ovation failed to meet certain regulatory requirements and thus required pre-marketing approval from the FDA, which Ovation did not have.  Thereafter, Osiris agreed with the FDA that it would not sell Ovation after December 31, 2014. 

In order to maintain access to Ovation following December 31, 2014, Distributor-1 agreed to take possession of a significant quantity of Ovation prior to December 31, 2014, and by December 2014 was in possession of approximately $1.8 million worth of Ovation.  Because Distributor-1 lacked the ability to pay for such a large purchase, the Ovation was shipped to Distributor-1 on consignment.  Because the product was on consignment, under governing accounting rules Osiris could not properly recognize revenue until Distributor-1 had sold the product to an end user or Distributor-1 otherwise agreed to purchase the product.

In or about December 2014, JACOBY requested that Owner-1 convert some or all of the consigned inventory to inventory owned by Distributor-1 by December 31, 2014.  To the extent other revenue recognition criteria were satisfied, completion of the actual sale of the inventory to Distributor-1 by December 31, 2014, would have allowed Osiris to recognize revenue for that product in 2014 and reference that revenue in the 2014 10-K it would subsequently file.

Notwithstanding internal pressure to make sales, however, JACOBY and Owner-1 did not reach a final agreement regarding the conversion of the consigned inventory until at least in or about January 2015.  Despite the fact that no agreement was reached in 2014, Osiris, at the direction of JACOBY, booked approximately $1.1 million in revenue related to the conversion of consignment product in the fourth quarter of 2014 (the “Distributor-1 Transaction”).

Jacoby Conveys False Information to Auditors After Improper Accounting Is Questioned

In or about October 2015, the Company’s auditors (the “Auditors”), in connection with an inspection by the Public Company Accounting Oversight Board (the “PCAOB”), requested additional documentation and information supporting Osiris’s recognition of revenue in December 2014 relating to the Distributor-1 Transaction.  In an effort to deceive the Auditors and the PCAOB, JACOBY provided or caused to be provided false, inaccurate, and misleading information to the Auditors. 

For example, in or about October 2015, JACOBY and others prepared a memorandum from Osiris to its Auditors attempting to justify the recognition of $1.1 million of revenue from the Distributor-1 Transaction in the fourth quarter of 2014.  In the memorandum, JACOBY falsely represented that on December 31, 2014, JACOBY had “discussed the sale terms with [Owner-1] via a conference call, and [Owner-1] agreed to purchase 933 units of Ovation for $1,072,950.”  As JACOBY well knew, no telephone call had taken place on December 31, 2014. 

Similarly, on or about November 5, 2015, JACOBY created a letter, backdated to December 29, 2014, purporting to memorialize an agreement between Osiris and Distributor-1 (the “Backdated Letter”).  That same day, JACOBY used his personal email account to send the Backdated Letter by email to Owner-1 stating:

“attached is something that I think you should find and send to me in an email saying you had this in your file from late last year, and just came across it – and that it does memorialize our several phone conversations . . . . . Call me if necessary, but write a wonderfully warm and convincing email, please – send it to my Osiris email.”

Owner-1 complied and sent the Backdated Letter to Jacoby’s Osiris email account.  JACOBY then forwarded Owner-1’s email containing the fraudulent Backdated Letter to the CEO and the then-CFO of Osiris, who forwarded the document to the Auditors. 

*                *                *
           
PHILIP JACOBY, 65, pled guilty to one count of making fraudulent statements to Osiris’s auditors, which carries a maximum sentence of 20 years in prison.  The defendant also faces a maximum fine of $5 million.  Sentencing before Judge Cote has been scheduled for February 2, 2018, at 11:00 a.m.    

The maximum potential sentence in this case is prescribed by Congress and is provided here for informational purposes only, as any sentencing of the defendant will be determined by a judge.    
           
Mr. Kim praised the investigative work of the United States Postal Inspection Service and also thanked the SEC, which filed a parallel civil case today.

This case is being handled by the Office’s Securities and Commodities Fraud Task Force. Assistant U.S. Attorneys Rebecca Mermelstein, Brendan F. Quigley, and Daniel B. Tehrani are in charge of the prosecution.
Topic(s): 
Financial Fraud
Component(s): 
Press Release Number: 
17-358

United States: US District Court Sanctions Weight-Loss Supplement ...

Mondaq News Alerts-6 hours ago
The FTC alleged that, in 2009, the defendants were violating the 2008 order by marketing four new dietary supplements with weight-loss claims that lacked the ...

Trump Picks Antitrust Lawyer to Head FTC, Leaving Uncertain ...

Natural Products INSIDER (blog)-2 hours ago
Katie Bond, an attorney in Washington who has responded to FTC investigations on behalf of business clients including the dietary supplement industry, said ...

Corruption, doping issues aired at global Olympic meeting

Salt Lake Tribune-2 hours ago
Officials met one day after an International Olympic Committee panel investigating an alleged Russian doping conspiracy at the 2014 Sochi Olympics found ...

FDA Commissioner Gottlieb Grants DQSA Coalition Meeting Request - International Academy of Compounding Pharmacists

FDA Commissioner Gottlieb Grants DQSA Coalition Meeting Request - International Academy of Compounding Pharmacists

FDA Announces PCAC Meeting to Occur on November 20-21, 2017 - International Academy of Compounding Pharmacists

FDA Announces PCAC Meeting to Occur on November 20-21, 2017 - International Academy of Compounding Pharmacists

FDA commissioner warns drug companies of 'disruptive' regulations ...

CNBC-3 hours ago
The FDA could take actions on opioids that drugmakers may dislike, FDACommissioner Scott Gottlieb says. "We're at a point in this crisis that we're going to ...

Just Think: What Amazon Could Do to the Pharmacy Business

Wall Street Journal-19 minutes ago
Amazon is considering a move into the pharmacy business, the Journal reported last weekend. Just imagine the special cross-marketing touch the retail giant ...

Georgia Pharmacy Owners Ordered to Pay $5M for Illegal Pain Med ...

Insurance Journal-11 hours ago
A husband and wife who owned an Atlanta pharmacy accused of supplying drugs to pill mill patients have been ordered to pay $5 million to state agencies that ...

Amazon should buy these companies if it wants to get into selling ...

CNBC-1 hour ago
So we asked 5 experts for their predictions on the companies that Amazon might look to acquire if it decides to move ahead with becoming an online pharmacy.